RxDoctor Payments Data

Julie Budinger

Gerontology · Charleston, WVNPI 1508894320

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations.

$1,667in general payments, 2019–2025

Across 29 payments — averaging $57.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$350
  • Boehringer Ingelheim$322
  • Actelion Pharmaceuticals US, Inc.$298
  • AstraZeneca$278
  • E.r. Squibb & Sons, L.L.C.$185
  • Pfizer$121
  • plus $114 from 3 others

What the payments were for

  • Food & beverage$1,667100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gerontology providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$26,650
Medicare patients
163
Services billed
334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan188$218,498
FarxigaDapagliflozin Propanediol157$150,264
JardianceEmpagliflozin85$123,762
Torsemide181$3,741
Spironolactone529$2,822
Isosorbide Dinitrate32$2,606
Metoprolol Succinate239$2,564
Eplerenone23$1,825
Hydralazine Hcl80$958
Furosemide208$859
Losartan Potassium111$627
Carvedilol67$616
Potassium Chloride50$456
Isosorbide Mononitrate ErIsosorbide Mononitrate16$189
Metolazone17$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$35$218,498188 claims
AstraZenecaFarxiga$278$150,264157 claims
Boehringer IngelheimJardiance$322$123,76285 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gerontology providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other gerontology in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →